Literature DB >> 34073538

The Endless Sources of Hepatocellular Carcinoma Heterogeneity.

Marina Barcena-Varela1,2,3, Amaia Lujambio1,2,3,4.   

Abstract

Hepatocellular carcinoma (HCC) represents a global health problem. The incidence keeps increasing and current therapeutic options confer limited benefits to the patients. Tumor heterogeneity plays a central role in this context, limiting the availability of predictive biomarkers and complicating the criteria used to choose the most suitable therapeutic option. HCC heterogeneity occurs at different levels: within the population (inter-patient heterogeneity) and within tumors from the same patient (intra-patient and intra-tumor heterogeneity). Experts in the field have made many efforts to classify the patients based on clinicopathological characteristics and molecular signatures; however, there is still much work ahead to be able to integrate the extra-tumor heterogeneity that emerges from the complexity of the tumor microenvironment, which plays a critical role in the pathogenesis of the disease and therapy responses. In this review, we summarize tumor intrinsic and extrinsic sources of heterogeneity of the most common etiologies of HCC and summarize the most recent discoveries regarding the evolutionary trajectory of liver cancer cells and the influence of tumor-extrinsic factors such as the microbiome and the host immune system. We further highlight the potential of novel high-throughput methodologies to contribute to a better understanding of this devastating disease and to the improvement of the clinical management of patients.

Entities:  

Keywords:  hepatocellular carcinoma; heterogeneity; microenvironment; molecular mechanisms; risk factors

Year:  2021        PMID: 34073538     DOI: 10.3390/cancers13112621

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  109 in total

1.  Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.

Authors:  Kuen-Feng Chen; Hui-Ling Chen; Wei-Tien Tai; Wen-Chi Feng; Chih-Hung Hsu; Pei-Jer Chen; Ann-Lii Cheng
Journal:  J Pharmacol Exp Ther       Date:  2011-01-04       Impact factor: 4.030

2.  Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

Authors:  Augusto Villanueva; Clara Alsinet; Kilangsungla Yanger; Yujin Hoshida; Yiwei Zong; Sara Toffanin; Leonardo Rodriguez-Carunchio; Manel Solé; Swan Thung; Ben Z Stanger; Josep M Llovet
Journal:  Gastroenterology       Date:  2012-09-11       Impact factor: 22.682

Review 3.  Hepatocellular carcinoma in the setting of alcohol-related liver disease.

Authors:  Nathalie Ganne-Carrié; Pierre Nahon
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

Review 4.  Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.

Authors:  Christian Bréchot
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.

Authors:  Tae-Hee Um; Haeryoung Kim; Bong-Kyeong Oh; Myoung Soo Kim; Kyung Sik Kim; Guhung Jung; Young Nyun Park
Journal:  J Hepatol       Date:  2010-10-29       Impact factor: 25.083

6.  Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Authors:  Jean-Charles Nault; Gabrielle Couchy; Charles Balabaud; Guillaume Morcrette; Stefano Caruso; Jean-Frederic Blanc; Yannick Bacq; Julien Calderaro; Valérie Paradis; Jeanne Ramos; Jean-Yves Scoazec; Viviane Gnemmi; Nathalie Sturm; Catherine Guettier; Monique Fabre; Eric Savier; Laurence Chiche; Philippe Labrune; Janick Selves; Dominique Wendum; Camilla Pilati; Alexis Laurent; Anne De Muret; Brigitte Le Bail; Sandra Rebouissou; Sandrine Imbeaud; Paulette Bioulac-Sage; Eric Letouzé; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2016-12-07       Impact factor: 22.682

7.  The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.

Authors:  Jérôme Boursier; Olaf Mueller; Matthieu Barret; Mariana Machado; Lionel Fizanne; Felix Araujo-Perez; Cynthia D Guy; Patrick C Seed; John F Rawls; Lawrence A David; Gilles Hunault; Frédéric Oberti; Paul Calès; Anna Mae Diehl
Journal:  Hepatology       Date:  2016-01-13       Impact factor: 17.425

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

10.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Authors:  Yang-Lin Liu; Helen L Reeves; Alastair D Burt; Dina Tiniakos; Stuart McPherson; Julian B S Leathart; Michael E D Allison; Graeme J Alexander; Anne-Christine Piguet; Rodolphe Anty; Peter Donaldson; Guruprasad P Aithal; Sven Francque; Luc Van Gaal; Karine Clement; Vlad Ratziu; Jean-Francois Dufour; Christopher P Day; Ann K Daly; Quentin M Anstee
Journal:  Nat Commun       Date:  2014-06-30       Impact factor: 14.919

View more
  4 in total

1.  Proton beam therapy to bridge or downstage locally advanced hepatocellular carcinoma to living donor liver transplantation.

Authors:  Chao-Long Chen; Aldwin D Ong; Jen-Yu Cheng; Chee-Chien Yong; Chih-Che Lin; Chih-Yi Chen; Yu-Fan Cheng
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

Review 2.  Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity.

Authors:  Shirley Lewis; Laura Dawson; Aisling Barry; Teodor Stanescu; Issa Mohamad; Ali Hosni
Journal:  JHEP Rep       Date:  2022-05-14

Review 3.  Biochemical Mechanisms of Sirtuin-Directed Protein Acylation in Hepatic Pathologies of Mitochondrial Dysfunction.

Authors:  Courtney D McGinnis; Erin Q Jennings; Peter S Harris; James J Galligan; Kristofer S Fritz
Journal:  Cells       Date:  2022-06-28       Impact factor: 7.666

4.  High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma.

Authors:  Yong-Guang Wei; Cheng-Kun Yang; Zhong-Liu Wei; Xi-Wen Liao; Yong-Fei He; Xin Zhou; Hua-Sheng Huang; Chen-Lu Lan; Chuang-Ye Han; Tao Peng
Journal:  Int J Gen Med       Date:  2022-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.